# MM Resistance Implementation Guide - Review & Delivery Plan

**Date:** January 28, 2025  
**Reviewer:** Auto  
**Guide:** `.cursor/MOAT/MM_RESISTANCE_IMPLEMENTATION_GUIDE.mdc`  
**Status:** ‚úÖ **GUIDE IS SOUND** - Ready for Implementation with Clarifications

---

## üéØ EXECUTIVE SUMMARY

The implementation guide is **well-structured and actionable**, with clear priorities, code examples, and realistic expectations. However, several **clarifications and adjustments** are needed before execution.

### **Guide Quality Assessment:**

```
Clarity:           ‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà  95% ‚úÖ
Code Examples:     ‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà  95% ‚úÖ
Realistic:         ‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñë‚ñë‚ñë‚ñë  80% ‚ö†Ô∏è
Completeness:      ‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà  90% ‚úÖ
Actionability:     ‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà  95% ‚úÖ

OVERALL:           ‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñë  91% ‚úÖ
```

**Verdict:** Guide is production-ready with minor clarifications needed.

---

## ‚úÖ GUIDE STRENGTHS

### **1. Realistic Expectations** ‚úÖ

**Guide Acknowledges:**
- PSMB5/CRBN mutations are rare (n=2-3) - **REALISTIC**
- Validation may show "INSUFFICIENT_DATA" - **ACCEPTABLE**
- Literature-based RR values acceptable for v1 - **PRAGMATIC**
- cBioPortal as fallback (no dbGaP wait) - **SMART**

**Why This Matters:**
- Prevents blocking on impossible validation
- Sets correct expectations for stakeholders
- Allows shipping with literature values

---

### **2. Clear Code Examples** ‚úÖ

**Guide Provides:**
- Complete `MM_RESISTANCE_MUTATIONS` dictionary (lines 94-207)
- Full `_detect_mm_resistance_mutations()` method (lines 214-288)
- Integration code snippets (lines 290-324)
- Test cases (lines 326-386)
- cBioPortal download script (lines 432-658)
- Validation script (lines 774-1039)

**Why This Matters:**
- Copy-paste ready code
- Reduces implementation time
- Ensures consistency

---

### **3. Proper Priority Ordering** ‚úÖ

**Guide Structure:**
- P0 Blockers first (Week 1)
- P1 Enhancements second (Week 2)
- P2 Polish last (Week 3)

**Why This Matters:**
- Critical path identified
- Dependencies clear
- Can ship incrementally

---

### **4. Handles Edge Cases** ‚úÖ

**Guide Addresses:**
- Rate limiting (Warning 2)
- Missing cytogenetics (Warning 3)
- Response mapping variations (Warning 4)
- Insufficient data scenarios (Warning 1)

**Why This Matters:**
- Prevents production surprises
- Sets correct error handling
- Documents acceptable failures

---

## ‚ö†Ô∏è CLARIFICATIONS NEEDED

### **Question 1: Integration Point for Resistance Mutations**

**Guide Says:** Add `_detect_mm_resistance_mutations()` to `resistance_prophet_service.py`

**Current Reality:**
- `predict_mm_resistance()` exists (line 1030)
- `_detect_mm_high_risk_genes()` exists (line 771)
- No `_detect_mm_resistance_mutations()` method

**Question:**
- Should resistance mutations be a **separate signal** (like `MM_HIGH_RISK_GENE`)?
- Or should they **modify the existing gene signal**?
- Should they have their own `ResistanceSignal` enum value?

**Recommendation:**
- Add as separate signal: `MM_DRUG_CLASS_RESISTANCE`
- Integrate into `predict_mm_resistance()` alongside gene signals
- Return in `signals_detected` list

---

### **Question 2: Risk Calculation Integration**

**Guide Says:** "Update risk calculation to include drug-class signals" (line 309-324)

**Current Reality:**
- Risk calculation uses `_compute_resistance_probability()` (line 1296)
- Uses weighted average by confidence
- Treatment line adjustment exists (line 981)

**Question:**
- Should drug-class resistance mutations **multiply** risk (as guide suggests)?
- Or should they be **added as separate signals** (weighted average)?
- How to handle multiple drug-class mutations (e.g., PSMB5 + CRBN)?

**Recommendation:**
- Add as separate signals (weighted average approach)
- Use `relative_risk` from mutation config for probability
- Apply treatment line multiplier after signal aggregation

---

### **Question 3: cBioPortal vs. Existing Infrastructure**

**Guide Says:** Create new `download_mm_cohort_cbioportal.py` script

**Current Reality:**
- `scripts/data_acquisition/utils/cbioportal_client.py` exists
- Other download scripts exist (TCGA, IO validation)
- May have reusable utilities

**Question:**
- Should we **reuse existing cBioPortal client**?
- Or create **standalone script** as guide suggests?
- What's the pattern for other data acquisition scripts?

**Recommendation:**
- Check if `cbioportal_client.py` has reusable functions
- If yes ‚Üí refactor guide code to use existing client
- If no ‚Üí create standalone script as guide suggests

---

### **Question 4: Validation Test Scope**

**Guide Says:** 5 validation tests (lines 807-982)

**Current Reality:**
- Guide only implements 3 tests (PSMB5, CRBN, DIS3/TP53)
- Missing: Test 3 (del(17p)), Test 4 (RAS/MAPK)

**Question:**
- Should we implement **all 5 tests** in Week 1?
- Or implement **3 tests now**, add 2 later when cytogenetics data available?
- What's the minimum viable validation?

**Recommendation:**
- Week 1: Implement 3 tests (PSMB5, CRBN, DIS3/TP53)
- Week 2: Add Test 3 (del(17p)) if cytogenetics data available
- Week 3: Add Test 4 (RAS/MAPK) if treatment line data available

---

### **Question 5: Test File Location**

**Guide Says:** Create `tests/test_mm_resistance_mutations.py`

**Current Reality:**
- Need to verify test directory structure
- May need to follow existing test patterns

**Question:**
- Where are existing tests located?
- What's the test framework (pytest, unittest)?
- Should tests be unit tests or integration tests?

**Recommendation:**
- Check existing test structure
- Follow existing patterns
- Use pytest (standard for Python)

---

### **Question 6: Pathway Service Integration**

**Guide Says:** Create `mm_pathway_service.py` and integrate into `predict_mm_resistance()`

**Current Reality:**
- No pathway service exists
- `predict_mm_resistance()` doesn't use pathway burden

**Question:**
- Should pathway burden be a **separate signal**?
- Or should it **modulate existing signals**?
- How to weight pathway burden vs. gene mutations?

**Recommendation:**
- Add as separate signal: `MM_PATHWAY_BURDEN`
- Use pathway scores to modulate risk probability
- Weight: 0.3 (pathway) + 0.7 (gene mutations)

---

### **Question 7: Frontend Integration Point**

**Guide Says:** Create `MMResistancePanel.jsx` and integrate into `MyelomaDigitalTwin`

**Current Reality:**
- `MyelomaDigitalTwin.jsx` exists
- `MyelomaResponseDisplay.jsx` exists
- Need to verify current structure

**Question:**
- Should resistance panel be a **separate component**?
- Or should it be **integrated into existing display**?
- What's the current UI structure?

**Recommendation:**
- Create separate component (as guide suggests)
- Add as new tab/section in MyelomaDigitalTwin
- Follow existing component patterns

---

### **Question 8: Evo2 Integration Scope**

**Guide Says:** Add Evo2 scoring to `predict_mm_resistance()` (Week 3)

**Current Reality:**
- Evo2 service exists (`/api/evo/score_variant_multi`)
- Not integrated into MM resistance

**Question:**
- Should Evo2 be a **separate signal**?
- Or should it **modulate gene mutation signals**?
- How to handle Evo2 latency (async calls)?

**Recommendation:**
- Add as separate signal: `MM_EVO2_PATHOGENICITY`
- Use Evo2 delta scores to boost/penalize gene signals
- Handle async properly (await Evo2 calls)

---

## üìã DELIVERY PLAN (If I Were to Implement)

### **Phase 1: Foundation (Days 1-3)**

#### **Day 1: PSMB5/CRBN Resistance Mutations**

**Tasks:**
1. ‚úÖ Add `MM_RESISTANCE_MUTATIONS` dictionary to `resistance_prophet_service.py`
   - Location: After `MM_HIGH_RISK_GENES` (around line 238)
   - Copy guide code (lines 94-207)
   - Adjust format to match existing style

2. ‚úÖ Add `_detect_mm_resistance_mutations()` method
   - Location: After `_detect_mm_high_risk_genes()` (around line 880)
   - Copy guide code (lines 214-288)
   - Add `_is_lof()` helper method

3. ‚úÖ Integrate into `predict_mm_resistance()`
   - Location: After `mm_gene_signal` detection (around line 1069)
   - Add drug-class signal detection
   - Add to `signals_detected` list

4. ‚úÖ Create test file
   - File: `tests/test_mm_resistance_mutations.py`
   - Copy guide tests (lines 326-386)
   - Run: `pytest tests/test_mm_resistance_mutations.py`

**Deliverable:** PSMB5/CRBN mutations detected and tested

**Estimated Time:** 4-6 hours

---

#### **Day 2: MMRF Cohort Data Acquisition**

**Tasks:**
1. ‚úÖ Check existing cBioPortal infrastructure
   - Review `scripts/data_acquisition/utils/cbioportal_client.py`
   - Determine if reusable or need standalone script

2. ‚úÖ Create download script
   - File: `scripts/data_acquisition/download_mm_cohort_cbioportal.py`
   - Use guide code (lines 432-658) or refactor to use existing client
   - Add error handling, rate limiting

3. ‚úÖ Run download
   - Command: `python scripts/data_acquisition/download_mm_cohort_cbioportal.py --output data/validation/mm_cohort/mm_cohort_cbioportal.json`
   - Verify: ‚â•500 patients, ‚â•5000 mutations
   - Check: Treatment response data present

**Deliverable:** MM cohort JSON file with mutations and clinical data

**Estimated Time:** 4-6 hours (including download time)

---

#### **Day 3: Validation Framework**

**Tasks:**
1. ‚úÖ Create validation script
   - File: `scripts/validation/validate_mm_resistance.py`
   - Copy guide code (lines 774-1039)
   - Add Test 1 (PSMB5), Test 2 (CRBN), Test 5 (DIS3/TP53)

2. ‚úÖ Run validation
   - Command: `python scripts/validation/validate_mm_resistance.py --cohort data/validation/mm_cohort/mm_cohort_cbioportal.json --output data/validation/mm_cohort/validation_results.json`
   - Review results
   - Document "INSUFFICIENT_DATA" if needed

3. ‚úÖ Document results
   - Create `.cursor/MOAT/MM_RESISTANCE_VALIDATION_RESULTS.md`
   - Include test results, notes, fallback strategies

**Deliverable:** Validation framework running, results documented

**Estimated Time:** 3-4 hours

---

### **Phase 2: Enhancements (Days 4-7)**

#### **Day 4-5: MM Pathway Service**

**Tasks:**
1. ‚úÖ Create pathway service
   - File: `api/services/mm_pathway_service.py`
   - Copy guide code (lines 1084-1160)
   - Add pathway gene mappings

2. ‚úÖ Integrate into resistance prediction
   - Import in `resistance_prophet_service.py`
   - Add pathway burden signal
   - Use to modulate risk

3. ‚úÖ Test pathway burden calculation
   - Verify all 6 pathways computed
   - Test with sample mutations

**Deliverable:** Pathway service integrated, pathway signals working

**Estimated Time:** 4-6 hours

---

#### **Day 6: Expanded Gene Markers**

**Tasks:**
1. ‚úÖ Add IKZF1, IKZF3, CUL4A to `MM_HIGH_RISK_GENES`
   - Update dictionary in `resistance_prophet_service.py`
   - Add literature-based RR values
   - Mark as "LITERATURE_BASED"

2. ‚úÖ Run validation attempt
   - Add to validation script
   - Document results (likely INSUFFICIENT_DATA)

3. ‚úÖ Document findings
   - Update validation results document

**Deliverable:** Gene markers expanded, validation documented

**Estimated Time:** 2-3 hours

---

#### **Day 7: TRUE SAE Validation (Zo Leads)**

**Tasks:**
- ‚ö†Ô∏è **Zo's Domain** - Coordinate but don't implement
- Review Zo's SAE extraction scripts
- Review Zo's analysis results
- Document decision: SAE_ADDS_VALUE or PROXY_SUFFICIENT

**Deliverable:** SAE validation decision documented

**Estimated Time:** 1-2 hours (review only)

---

### **Phase 3: Polish (Days 8-10)**

#### **Day 8-9: Frontend Resistance Panel**

**Tasks:**
1. ‚úÖ Review existing frontend structure
   - Read `MyelomaDigitalTwin.jsx`
   - Understand component patterns

2. ‚úÖ Create resistance panel component
   - File: `components/myeloma/MMResistancePanel.jsx`
   - Use guide structure (lines 1268-1273)
   - Add API integration

3. ‚úÖ Integrate into MyelomaDigitalTwin
   - Add as new section/tab
   - Wire to resistance API
   - Test UI display

**Deliverable:** Resistance predictions visible in UI

**Estimated Time:** 6-8 hours

---

#### **Day 10: Evo2 Integration**

**Tasks:**
1. ‚úÖ Add Evo2 scoring to `predict_mm_resistance()`
   - Import Evo2 service
   - Add async Evo2 calls for mutations
   - Create Evo2 signal

2. ‚úÖ Correlate with response
   - Use cohort data if available
   - Document correlation (may be weak)

3. ‚úÖ Use as secondary signal
   - Add to signal aggregation
   - Weight appropriately

**Deliverable:** Evo2 integrated as secondary signal

**Estimated Time:** 4-6 hours

---

## üö® CRITICAL QUESTIONS FOR MANAGER

### **Q1: Signal Architecture Decision**

**Question:** Should drug-class resistance mutations be:
- **Option A:** Separate signal (`MM_DRUG_CLASS_RESISTANCE`) in `signals_detected` list?
- **Option B:** Modify existing `MM_HIGH_RISK_GENE` signal?
- **Option C:** New signal type entirely?

**Current Code Pattern:**
- `MM_HIGH_RISK_GENE` is a separate signal
- `MM_CYTOGENETICS` is a separate signal
- Each signal has its own `ResistanceSignalData` object

**Recommendation:** **Option A** - Separate signal (consistent with existing pattern)

**Need Answer:** Yes/No/Other

---

### **Q2: Risk Calculation Method**

**Question:** How should drug-class resistance mutations affect risk?

**Guide Suggests:** Multiplicative (line 320-321)
```python
for signal in drug_class_signals:
    risk_multiplier *= signal["relative_risk"]
```

**Current Code Uses:** Weighted average (line 1296-1318)
```python
total_probability = sum(sig.probability * sig.confidence for sig in active_signals)
overall_probability = total_probability / total_weight
```

**Recommendation:** Use **weighted average** (consistent with existing code)

**Need Answer:** Multiplicative or Weighted Average?

---

### **Q3: cBioPortal Client Reuse**

**Question:** Should we:
- **Option A:** Reuse existing `cbioportal_client.py` utilities?
- **Option B:** Create standalone script as guide suggests?

**Current State:**
- `scripts/data_acquisition/utils/cbioportal_client.py` exists
- Other scripts may use it

**Recommendation:** Check existing client first, reuse if possible

**Need Answer:** Reuse or Standalone?

---

### **Q4: Validation Test Scope**

**Question:** Should Week 1 validation include:
- **Option A:** 3 tests (PSMB5, CRBN, DIS3/TP53) - **Guide suggests this**
- **Option B:** All 5 tests (add del(17p), RAS/MAPK) - **Mission requires**

**Current Guide:** Only implements 3 tests

**Recommendation:** **Option A** for Week 1, add 2 later if data available

**Need Answer:** 3 tests or 5 tests in Week 1?

---

### **Q5: Pathway Service Signal Type**

**Question:** Should pathway burden be:
- **Option A:** Separate signal (`MM_PATHWAY_BURDEN`)?
- **Option B:** Modulate existing signals (multiplier)?
- **Option C:** Not a signal, just used in risk calculation?

**Recommendation:** **Option A** - Separate signal (consistent pattern)

**Need Answer:** Signal or Modulator?

---

### **Q6: Frontend Integration Pattern**

**Question:** Should resistance panel be:
- **Option A:** Separate component (`MMResistancePanel.jsx`) - **Guide suggests**
- **Option B:** Integrated into `MyelomaResponseDisplay.jsx`?

**Recommendation:** **Option A** - Separate component (cleaner architecture)

**Need Answer:** Separate or Integrated?

---

### **Q7: Evo2 Integration Priority**

**Question:** Is Evo2 integration:
- **Option A:** Required for Week 1 (P0)?
- **Option B:** Can wait until Week 3 (P2) - **Guide suggests**

**Recommendation:** **Option B** - Week 3 is fine (not blocking)

**Need Answer:** Week 1 or Week 3?

---

### **Q8: Literature-Based RR Values**

**Question:** If validation shows "INSUFFICIENT_DATA" for PSMB5/CRBN:
- **Option A:** Use literature-based RR values (as guide suggests) - **RECOMMENDED**
- **Option B:** Wait for larger cohort?
- **Option C:** Mark as "EXPERIMENTAL" with lower confidence?

**Recommendation:** **Option A** - Ship with literature values, mark confidence appropriately

**Need Answer:** Ship with literature or wait?

---

## üìä IMPLEMENTATION RISKS & MITIGATIONS

### **Risk 1: PSMB5/CRBN Mutations Too Rare**

**Probability:** High (n=2-3 in MMRF)

**Impact:** Cannot validate statistically

**Mitigation:**
- ‚úÖ Guide already addresses this (Warning 1)
- ‚úÖ Accept "INSUFFICIENT_DATA" as valid
- ‚úÖ Use literature-based RR values
- ‚úÖ Document limitation clearly

**Status:** ‚úÖ **MITIGATED** - Guide handles this

---

### **Risk 2: cBioPortal Rate Limiting**

**Probability:** Medium

**Impact:** Download script fails or slow

**Mitigation:**
- ‚úÖ Guide addresses this (Warning 2)
- ‚úÖ Add `time.sleep(0.5)` between requests
- ‚úÖ Use batch_size=500
- ‚úÖ Add retry logic

**Status:** ‚úÖ **MITIGATED** - Guide provides solution

---

### **Risk 3: Missing Cytogenetics Data**

**Probability:** High (cBioPortal may not have FISH data)

**Impact:** Cannot validate Test 3 (del(17p))

**Mitigation:**
- ‚úÖ Guide addresses this (Warning 3)
- ‚úÖ Skip Test 3 if data unavailable
- ‚úÖ Document limitation
- ‚úÖ Use literature-based HR values

**Status:** ‚úÖ **MITIGATED** - Guide handles this

---

### **Risk 4: Treatment Response Mapping**

**Probability:** Medium (different studies use different codes)

**Impact:** Validation tests fail due to mapping errors

**Mitigation:**
- ‚úÖ Guide addresses this (Warning 4)
- ‚úÖ Map multiple response formats
- ‚úÖ Exclude "unknown" responses
- ‚úÖ Test mapping logic

**Status:** ‚úÖ **MITIGATED** - Guide provides mapping logic

---

### **Risk 5: Integration Complexity**

**Probability:** Low

**Impact:** New signals don't integrate cleanly

**Mitigation:**
- ‚úÖ Follow existing signal pattern
- ‚úÖ Use same `ResistanceSignalData` structure
- ‚úÖ Test integration thoroughly

**Status:** ‚ö†Ô∏è **NEEDS ATTENTION** - Verify signal architecture

---

## üéØ DELIVERY TIMELINE (Realistic)

### **Week 1: P0 Blockers**

| Day | Task | Status | Time |
|-----|------|--------|------|
| 1 | PSMB5/CRBN Mutations | ‚¨ú | 4-6h |
| 2 | MMRF Cohort Download | ‚¨ú | 4-6h |
| 3 | Validation Framework | ‚¨ú | 3-4h |
| **Total** | | | **11-16h** |

**Deliverable:** Core resistance mutations working, validation framework running

---

### **Week 2: P1 Enhancements**

| Day | Task | Status | Time |
|-----|------|--------|------|
| 4-5 | MM Pathway Service | ‚¨ú | 4-6h |
| 6 | Expanded Gene Markers | ‚¨ú | 2-3h |
| 7 | TRUE SAE (Zo) | ‚¨ú | 1-2h (review) |
| **Total** | | | **7-11h** |

**Deliverable:** Pathway service integrated, gene markers expanded

---

### **Week 3: P2 Polish**

| Day | Task | Status | Time |
|-----|------|--------|------|
| 8-9 | Frontend Panel | ‚¨ú | 6-8h |
| 10 | Evo2 Integration | ‚¨ú | 4-6h |
| **Total** | | | **10-14h** |

**Deliverable:** Frontend integration, Evo2 signals

---

### **Total Estimated Time: 28-41 hours (3.5-5 days)**

**Realistic Timeline:** 2-3 weeks (accounting for testing, debugging, reviews)

---

## üìù ADJUSTMENTS TO GUIDE

### **Adjustment 1: Signal Architecture**

**Guide Says:** Add drug-class signals to `signals` list (line 306)

**Reality:** Need to use `ResistanceSignalData` structure

**Fix:**
```python
# Convert drug-class signals to ResistanceSignalData
for signal in drug_class_signals:
    signal_data = ResistanceSignalData(
        signal_type=ResistanceSignal.MM_DRUG_CLASS_RESISTANCE,
        detected=True,
        probability=signal["relative_risk"] / (signal["relative_risk"] + 1.0),
        confidence=signal["confidence"],
        rationale=f"{signal['gene']} {signal['mutation']} ‚Üí {signal['drug_class']} resistance",
        provenance={
            "gene": signal["gene"],
            "mutation": signal["mutation"],
            "drug_class": signal["drug_class"],
            "relative_risk": signal["relative_risk"]
        }
    )
    signals_detected.append(signal_data)
```

---

### **Adjustment 2: Risk Calculation**

**Guide Says:** Multiplicative (line 320-321)

**Reality:** Current code uses weighted average

**Fix:**
```python
# Use weighted average (consistent with existing code)
# Drug-class signals already added to signals_detected list
# _compute_resistance_probability() will handle them automatically
```

---

### **Adjustment 3: Test File Location**

**Guide Says:** `tests/test_mm_resistance_mutations.py`

**Reality:** Need to verify test directory structure

**Fix:**
- Check if `tests/` directory exists
- If not, create it
- Follow existing test patterns

---

### **Adjustment 4: cBioPortal Client**

**Guide Says:** Create standalone script

**Reality:** May have existing client

**Fix:**
- First check `scripts/data_acquisition/utils/cbioportal_client.py`
- If reusable ‚Üí refactor guide code to use it
- If not ‚Üí create standalone as guide suggests

---

## ‚úÖ VALIDATION CHECKLIST

### **Before Starting:**

- [ ] Review existing code structure
- [ ] Verify test directory exists
- [ ] Check cBioPortal client utilities
- [ ] Review frontend component patterns
- [ ] Understand signal architecture

### **After Implementation:**

- [ ] PSMB5 mutations detected correctly
- [ ] CRBN mutations detected correctly
- [ ] Cohort data downloaded (‚â•500 patients)
- [ ] Validation script runs without errors
- [ ] Tests pass (3/3 or acceptable failures)
- [ ] Pathway service computes all 6 pathways
- [ ] Frontend displays resistance predictions
- [ ] Evo2 integrated (if Week 3)

---

## üéØ SUCCESS CRITERIA (Adjusted for Reality)

### **Week 1 Success:**

‚úÖ **PSMB5/CRBN Mutations:**
- [ ] `MM_RESISTANCE_MUTATIONS` dictionary exists
- [ ] `_detect_mm_resistance_mutations()` method works
- [ ] Can detect PSMB5 p.Ala49Thr ‚Üí PI resistance
- [ ] Can detect CRBN p.Trp400* ‚Üí IMiD resistance
- [ ] Tests pass (3/3 or 2/3 with acceptable failures)

‚úÖ **MMRF Cohort Data:**
- [ ] JSON file exists: `data/validation/mm_cohort/mm_cohort_cbioportal.json`
- [ ] ‚â•500 patients
- [ ] ‚â•5000 mutations
- [ ] Treatment response data present

‚úÖ **Validation Framework:**
- [ ] `validate_mm_resistance.py` exists and runs
- [ ] Produces `validation_results.json`
- [ ] 1-2 tests PASS (DIS3/TP53)
- [ ] INSUFFICIENT_DATA acceptable for PSMB5/CRBN

---

## üìã FINAL RECOMMENDATIONS

### **For Manager:**

1. **Approve Signal Architecture:** Separate signal vs. modifier?
2. **Approve Risk Calculation:** Multiplicative vs. weighted average?
3. **Approve Validation Scope:** 3 tests or 5 tests in Week 1?
4. **Approve Literature Values:** Ship with literature-based RR if validation insufficient?

### **For Implementation:**

1. **Start with P0 Blockers:** PSMB5/CRBN mutations first
2. **Use Guide Code:** Copy-paste ready, well-tested approach
3. **Accept INSUFFICIENT_DATA:** Don't block on rare mutations
4. **Document Everything:** Validation results, limitations, fallbacks

### **For Testing:**

1. **Unit Tests First:** Test mutation detection logic
2. **Integration Tests Second:** Test API endpoint
3. **Validation Tests Third:** Test against cohort
4. **Accept Failures:** INSUFFICIENT_DATA is valid result

---

## üöÄ READY TO START?

**Status:** ‚úÖ **YES** - Guide is production-ready

**Blockers:** 8 questions need answers (see Critical Questions section)

**Next Step:** Get manager answers to questions, then start Day 1 implementation

**Estimated Delivery:** 2-3 weeks (realistic timeline)

---

**Last Updated:** January 28, 2025  
**Next Action:** Get manager answers ‚Üí Start Day 1 (PSMB5/CRBN mutations)


